The pilot also reduced cancer drug costs by 20% compared to UnitedHealthcare's cancer drug costs nationally, and all treatments were evidence-based and in alignment with the recommendations of the nation's leading cancer centres.
This tool incorporates real-time guidelines from the National Comprehensive Cancer Network (NCCN) into the oncologists' decision-making process.
The online program showed physicians all available NCCN-recommended options during the request; choosing any one of these options resulted in an immediate approval. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) are trusted by health care professionals around the world to help them determine the best way to treat cancer patients.
UnitedHealthcare automatically approves coverage for all regimens that align with NCCN Guidelines. The online tool was developed by eviCore healthcare, which manages UnitedHealthcare's injectable chemotherapy programme.
Details of the study, "Transforming Prior Authorization to Decision Support," were published Oct. 18 in the peer-reviewed publication, Journal of Oncology Practice. The article was co-authored by Dr. Newcomer; Robert W. Carlson, M.D., CEO of NCCN; and Richard Weininger, M.D., senior strategic advisor and former chief medical officer of eviCore healthcare.
The programme will help advance cancer research and patient care by contributing to a database that will enable UnitedHealthcare to identify top-performing regimens by cancer type. The company plans to publish comparative results late next year.
This online programme was piloted by all medical oncology practices in Florida that are part of UnitedHealthcare's care provider network. The pilot was conducted over one year, from June 2014 to June 2015.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA